{"Clinical Trial ID": "NCT00014222", "Intervention": ["INTERVENTION 1:", "1st arm : CEF", "6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - in - Days 1 to 14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 to 5 Fluorouracil: 500 mg/m2 - IV - Days 1 and 8 + Continuous antibiotic prophylaxis with Cotrimoxazole 960 mg (i.e. 2 x 480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid", "Cyclophosphamide: 75, 600 and 830 mg/m2", "- Epirubicin hydrochloride: 60 mg/m2", "Fluoruracil: 500mg/m2", "INTERVENTION 2:", "Second arm: EC/T", "6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5\u03bcg/kg/day - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once a week (start within one week after start of protocol therapy as needed) 21 days after last EC (EC/T) administration 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days after last CA 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hours infusion", "Epoetin alfa: 40,000 IU", "- filgrastim: 5 mg/kg/day - days 2-13", "Cyclophosphamide: 75, 600 and 830 mg/m2", "Doxorubicin hydrochloride: 60 mg/m2", "Paclitaxel: 175 mg/m2"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A histologically confirmed adenocarcinoma of the breast that is potentially curable", "T0-4 (dermal involvement in pathology assessment only), N0-2, M0", "No clinical T4 disease", "Previously treated with one of the following treatments:", "Total mastectomy and level II axillary dissection", "* Partial mastectomy and level II axillary dissection with planned breast radiotherapy after completion of adjuvant chemotherapy*", "Patients with positive sentinel lymph node biopsy should undergo dissection of the level II axillary node or sufficient nodal sampling.", "If residual in situ or invasive microscopic disease is present at the margins of total or partial mastectomy, planned radiation therapy should also include stimulation of the tumour bed.", "No residual tumours in the axilla after dissection", "Positive axillary node", "The negative lymph nodes allowed if the tumour is 1 cm and 1 or more of the following criteria defining the high-risk disease of the negative nodes are satisfied:", "- Histological Class III or,", "- Negative estrogen receiver or,", "- Lymphatic/vascular invasion", "- Hormonal receptor status:", "Known status of estrogen receptors", "CHARACTERISTICS OF PATIENTS:", "Age:", "- 60 years and under", "Gender:", "Women", "Status of menopause:", "Pre- or post-menopausal", "Status:", "- ECOG 0-2", "Life expectancy:", "At least 5 years", "Haematopoietic:", "WBC 3.000/mm^3", "Number of platelets 100 000/mm^3", "Hepatic:", "Bilirubine 1.5 times the upper limit of normal (ULN)", "- Renal:", "\u2022 Creatinine 1.5 times LSN", "Cardiovascular disorders:", "LVEF limit of normal by MUGA or echocardiogram", "No arrhythmia requiring continuous treatment", "No congestive heart failure", "No coronary artery disease documented", "Other:", "No other malignancy, except:", "A skin cancer or a carcinoma of the basal cell or squamous cell properly treated in situ of the cervix", "A ductal or lobular carcinoma in situ that has been treated curatively by surgery alone", "Other prior malignancies (except breast cancer) treated curatively more than 5 years prior to entry into the study", "No serious underlying medical disease or psychiatric or addictive disorder that would prevent compliance with the study", "No known hypersensitivity to E. coli derivatives, mammalian cell derivatives or any study agent.", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective non-hormonal contraception", "THERAPE PRIOR CONCURENT:", "Biological therapy:", "No prior immunotherapy for breast cancer", "No pegfilgrastim or darbepoetin alfa (arm II)", "Allowed on arms 1 and 3 if necessary medically", "- Chemotherapy:", "No previous chemotherapy for breast cancer", "Endocrinotherapy:", "No prior hormonal treatment for breast cancer", "No concomitant hormone replacement therapy", "No selective oestrogen-receptor concomitant modulator (e.g. raloxifene for the treatment or prevention of osteoporosis)", "No concomitant oral contraceptives (i.e. contraceptive pills)", "No other co-inhibitors of aromatase", "Radiotherapy:", "See Disease Characteristics", "No prior radiation therapy for breast cancer", "Surgery:", "See Disease Characteristics", "No more than 12 weeks since the previous total or partial mastectomy (including reexcision of margins)", "Other:", "At least 30 days from previous experimental medicinal products", "No other concomitant experimental medicinal products", "\u00b7 Concomitant bisphosphonates for the treatment or prevention of osteoporosis are permitted"], "Results": ["Performance measures:", "\u2022 Disease-free survival", "\u2022 Disease-free survival was defined as the period from randomization to recurrence of primary disease. Local or nodal recurrence and metastatic disease were considered a recurrence of the primary tumour. Patients who had controlateral breast cancer or second primary malignancies, or died from a cause other than the disease were censored without relapse at the time of death.", "Time limit: 13 years", "Results 1:", "Title of arm/group: Arm 1: CEF", "Description of the arm/group: 6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - in - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8-5 Fluorouracil: 500 mg/m2 - IV - Days 1-8 + Continuous antibiotic prophylaxis with Cotrimoxazole 960 mg (i.e. 2 x 480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid", "Cyclophosphamide: 75, 600 and 830 mg/m2", "- Epirubicin hydrochloride: 60 mg/m2", "Fluoruracil: 500mg/m2", "Total number of participants analysed: 701", "Type of measure: Number of participants", "Unit of measure: Participants Recurrence of disease: 141 20.1%", "No recurrence: 560 79.9%", "Results 2:", "Title of arm/group: Arm 2: EC/T", "Description of the arm/group: 6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5\u03bcg/kg/day - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once a week (starting within one week after initiation of protocol therapy if required) 21 days after last EC (EC/T) administration 4 cycles - q 21 days (3 months) - Adriaticin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days after last CA 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV infusion of 3 hours", "Epoetin alfa: 40,000 IU", "- filgrastim: 5 mg/kg/day - days 2-13", "Cyclophosphamide: 75, 600 and 830 mg/m2", "Doxorubicin hydrochloride: 60 mg/m2", "Paclitaxel: 175 mg/m2", "Total number of participants analysed: 701", "Type of measure: Number of participants", "Unit of measure: Participants Recurrence of disease: 135 19.3%", "No recurrence: 566 80.7%"], "Adverse Events": ["Undesirable Events 1:", "Total: 83/780 (12.21 per cent)", "Hemoglobin 11/780 (1.62%)", "Transfusion: Blisters 0/680 (0.00 %)", "Transfusion: pRBCs 0/680 (0.00 %)", "- Febrile neutropenia 49/780 (7.21%)", "Ed. 1/680 (0.15%)", "Ischemia/infarction 0/680 (0.00 %)", "- Palpitations 0/680 (0.00 %)", "Pericardial infusion 0/680 (0.00 %)", "Keratite 1/780 (0.15%)", "Double vision 1/780 (0.15%)", "- Collision 1/780 (0.15%)", "Adverse Events 2:", "Total: 86/688 (12.50 per cent)", "Hemoglobin 15/688 (2.18 per cent)", "Transfusion: Blisters 1/688 (0.15%)", "- Transfusion: pRBC 1/688 (0.15%)", "- Febrile neutropenia 41/688 (5.96%)", "- Ed. 0/688 (0.00 %)", "Ischemia/infarction 0/688 (0.00 %)", "Palpitations 1/688 (0.15%)", "- Pericardial infusion 1/688 (0.15%)", "Keratite 0/688 (0.00 %)", "Double vision 0/688 (0.00 %)", "- Collision 0/688 (0.00 %)"]}